SpliceBio is a Spanish therapeutics company addressing the key limitations of current gene therapy. It harnesses its proprietary Protein Splicing platform to develop next-generation gene therapies, based on engineered inteins pioneered at the Muir Lab at Princeton University.

The company is building a product pipeline of gene therapies targeting inherited retinal diseases and other severe genetic diseases for which there is no cure. By applying single-session therapy early in the course of genetic diseases, SpliceBio aims to stop progression and minimize clinical symptoms, providing a long-term solution for patients who are suffering from a lack of therapeutic options. SpliceBio’s Protein Splicing technology offers significant potential to address conditions that otherwise cannot be treated, in cases where the necessary gene is too large to be delivered by traditional gene therapies using adeno-associated virus vectors.

In 2022, Gilde Healthcare invested in SpliceBio’s €50m Series A financing round to enable the company to build a pipeline of protein splicing gene therapy programs and advance its lead program on Stargardt disease to clinics.